Service for specialized journalist

Grünenthal Press Releases 2017

Welcome to Grünenthal's Press Overview

07 Sep 2017

Aging demographics require novel ideas in pain research

Copenhagen, 7 September, 2017. Significant unmet medical needs in the field of pain in Europe have made pain research more relevant than ever. On the occasion of the congress of the European Pain Federation EFIC®, young scientists from across Europe presented the results of their pain research projects, which focus on novel ideas with the potential for achieving major advances in pain Management.

More ...

01 Sep 2017

Mark Fladrich takes office as the new CCO of the Grünenthal Group

Aachen, Germany, September 1, 2017. The Grünenthal Group today announces that Mark Fladrich has taken office as new Chief Commercial Officer (CCO). Grünenthal is an entrepreneurial, science-based pharmaceutical company specialized in pain, gout and inflammation headquartered in Aachen, Germany. In his last appointment Mark Fladrich served as Area Vice President, Southern and Western Europe for AstraZeneca.

More ...

28 Aug 2017

Grünenthal Group successfully opens up to the capital market-related environment and experiences strong interest from investors

Aachen, Germany, 28. August 2017. Grünenthal GmbH issued a promissory note at the end of July 2017. The transaction was announced with a volume of € 150 million. Due to the strong interest of investors and the subsequent oversubscription, the initial transaction volume has been well exceeded and increased to € 300 million. Grünenthal diversifies its lenders and increases its lender base with the promissory note.

More ...

05 Jul 2017

Launch of the project: Modelling neuron-glia networks into a drug discovery platform for pain efficacious treatments (NGN-PET)

The new research project NGN-PET was launched in the framework of the Innovative Medicine Initiative (IMI), the largest public-private partnership (PPP) for health research worldwide co-funded by the EU and the European pharmaceutical industry. The NGN-PET consortium unites the expertise and knowledge of industry partners from the European Federation of Pharmaceutical Industries and Associations (EFPIA), small and medium-sized enterprises (SMEs) and academia. Together they will investigate neuron-glia interactions aiming to develop authentic cellular (co-culture) assays to discover improved treatments of neuropathic pain using neuronal and glial cell types derived from human induced pluripotent stem cells (iPSC), and their co-cultures. The primary objective is to provide a translational platform for the identification, validation and testing of neuropathic pain targets in preclinical and human-relevant test systems suitable for drug discovery.

More ...

13 Jun 2017

Grünenthal’s CEO demands intensive cooperation with all stakeholders to improve health care

Valletta, June 13, 2017 – During his speech at the Societal Impact of Pain symposium in Valletta, Malta, Gabriel Baertschi, CEO of Grünenthal and board member of the European Federation of Pharmaceutical Industries and Associations (EFPIA) emphasized the increased necessity of addressing the impact of pain on society. Not only is pain a major burden for those affected and one of the most common reasons for a doctor’s visit, but the societal burden of pain is also a major challenge for social systems in Europe. In the light of an aging society and an increasing number of chronic health conditions, a stronger focus on the societal impact of pain is necessary to secure excellent health care in Europe, in a long-term and sustainable manner.

More ...

07 Jun 2017

Grünenthal enters agreement with AstraZeneca to acquire global rights to migraine treatment Zomig® (Zolmitriptan)

Aachen, June 07, 2017 - The Grünenthal Group today announced that it has entered into an agreement with AstraZeneca for the global rights to Zomig® (Zolmitriptan) excluding Japan. Zomig® is indicated for the acute treatment of migraines and cluster headaches. The transaction is expected to be completed before the end of the second quarter of 2017, subject to regulatory clearances.

More ...

29 May 2017

Grünenthal obtained a Red Dot Product Design Award for its innovative system for post-operative pain management

Aachen, Germany, May 29, 2017. The Grünenthal Group, an R&D-driven, privately held international pharmaceutical company with headquarters in Aachen Germany, announced today that it has received the renowned Red Dot Product Design Award in the category life sciences and medicine for an innovative system for post-operative pain management. The “Red Dot” is given for good design and innovation. Patients are able to self-administer a pain drug using this system. The product has been available to patients in Western Europe since the first half of 2016.

More ...

23 May 2017

Cutting edge science in pain treatment in order to improve patients’ lives

EFIC-GRÜNENTHAL GRANT 2016 supports six young scientists in their advanced pain research projects

Brussels/Aachen, 23 May, 2017. The European Pain Federation EFIC® in cooperation with the pharmaceutical company Grünenthal announced that six young research scientists in the field of pain will be awarded an EFIC-GRÜNENTHAL Grant (E-G-G). This biennial grant, totalling € 200,000, supports up-and-coming pain scientists in translating their experimental project ideas into funded pain research projects.

More ...

10 May 2017

Grünenthal opens Innovation Hub in Boston as next step in strategy to drive external innovation in pain, specialty therapeutics and medical devices forward

Aachen, Germany – Wednesday May 10, 2017. Grünenthal, a worldwide leader in Pain, announced today that it has opened a new Innovation Hub in the Greater Boston area. Through this Innovation Hub, Grünenthal aims to identify promising projects in pain, inflammation, orphan diseases, and devices & technologies from the large number of projects in late discovery and early development in the region. By building collaborative networks, in close partnership with institutions in the Boston area – from entrepreneurial scientists to successful spin-outs and start-ups – Grünenthal will drive these projects through research and development (R&D) in order to address the need for innovation.

More ...

09 May 2017

Mark Fladrich appointed new Chief Commercial Officer (CCO) at Grünenthal

Aachen, Germany, May 09, 2017. The Grünenthal Group announced today that Mark Fladrich will take over the position as Chief Commercial Officer (CCO) responsible for the entire Global Commercial Organization. Currently Mark Fladrich is Area Vice President, Southern and Western Europe, at AstraZeneca, based in the UK. He will join Grünenthal effective September 1, 2017.

More ...

next [4]